Tonix Pharmaceuticals stock halted ahead of FDA approval news
Rocky Brands , Inc. (NASDAQ:RCKY) stock has experienced a notable downturn, reaching a 52-week low of $17.79. This price level reflects a significant retreat from more favorable positions in the past year, with the company’s shares declining 41.38% over the past six months. According to InvestingPro analysis, the stock appears undervalued despite maintaining a healthy dividend yield of 3.45% and 13 consecutive years of dividend payments. Investors are closely monitoring the stock as it navigates through the challenging market conditions that have contributed to this recent low point. The footwear manufacturer’s performance is being scrutinized for signs of a potential rebound or further decline in the coming quarters. With a P/E ratio of 11.73 and strong financial health indicators, InvestingPro offers additional insights through its comprehensive analysis and 10 key ProTips available to subscribers.
In other recent news, Rocky Brands Inc. reported its fourth-quarter 2024 financial results, showcasing a mixed performance. The company’s earnings per share (EPS) were $1.19, missing the forecasted $1.24, but it surpassed revenue expectations with $128.1 million, compared to the anticipated $127.16 million. Despite the EPS miss, Rocky Brands demonstrated resilience with a 1.7% year-over-year revenue increase and a significant debt reduction of 25.7% over the past year. The company also announced a new $7.5 million share repurchase program. Tariffs on China-sourced products increased by 10%, which the company acknowledged as a challenge. Analysts from Baird noted cautious retailer behavior impacting future sales, while the company remains optimistic about low single-digit revenue growth for 2025. Additionally, CFO Tom Robertson highlighted strategic efforts to mitigate tariff impacts, including pricing adjustments and vendor negotiations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.